Trelagliptin Succinate Intermediate CAS 865759-24-6 Purity >98.0% (HPLC)

Short Description:

Trelagliptin Succinate Intermediate-int D 

CAS: 865759-24-6

Purity: >98.0% (HPLC)

Appearance: Off-White to Light Yellow Crystal 

Intermediate of Trelagliptin Succinate (CAS: 1029877-94-8) for the treatment of Type 2 Diabetes

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Commercial Supply Trelagliptin Succinate Related Intermediates:
6-Chloro-3-Methyluracil CAS 4318-56-3
2-Cyano-5-Flurobenzyl Bromide CAS 421552-12-7
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
Trelagliptin Succinate Intermediate-int D CAS 865759-24-6
Trelagliptin Succinate CAS 1029877-94-8
Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name Trelagliptin Succinate Intermediate-int D 
Synonyms 2-((6-Chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile; 2-[(6-Chloro-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl)methyl]-4-fluorobenzonitrile
Impurity  Trelagliptin Impurity 17
Stock Status In Stock, Commercial Scale
CAS Number 865759-24-6
Molecular Formula C13H9ClFN3O2
Molecular Weight 293.68 g/mol
Density 1.49±0.10 g/cm3 
Storage Temp.  Cool & Dry Place 
COA & MSDS Available
Brand Ruifu Chemical

Specifications:

Items Inspection Standards Results
Appearance Off-White to Light Yellow Crystal
Conforms   
Identification
HPLC The retention time of test sample major peak complies to reference standard Conforms
IR - Infrared Spectrum IR Absorption spectra of sample and standard are concordant Conforms
Inspection
Loss on Drying <0.50% 0.3% 
Total Impurities <2.00% Conforms
Purity / Analysis Method >98.0% (HPLC)  99.1% 
Conclusion The product has been tested & complies with the specifications

Package/Storage/Shipping:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture. Avoid light; Airtight.
Shipping: Deliver to worldwide by FedEx / DHL Express. Provide fast and reliable delivery. 

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory AuditFactory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

TransportationBy Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom SynthesisCan provide custom synthesis services to best fit your research needs.

Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

Application:

2-((6-chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile (CAS: 865759-24-6) is used as an intermediate of Trelagliptin Succinate (CAS: 1029877-94-8). Trelagliptin Succinate, developed by Takeda, Japan, launched in March 2015, under the trade name Zafatek, is used to treat type 2 diabetes. Trelagliptin is an ultra-long-acting dipeptidyl peptidase IV(DPP-4) inhibitor by selectively and continuously inhibiting DPP-4 to control blood sugar levels. Trelagliptin is the first weekly hypoglycemic drug on the market, and similar DPP-4 inhibitors on the market need to be taken once a day. Zafatek medication advantages will undoubtedly provide more convenient treatment options for diabetic patients. It is expected to greatly improve the convenience and compliance of patients. on March 26, 2015, Japanese pharmaceutical giant Takeda announced that the new diabetes drug Zafatek was approved by Japan's Ministry of health, labor and welfare (MHLW) for the treatment of type 2 diabetes. The approval marks Zafatek becoming the first weekly oral hypoglycemic drug on the market in the world, and also represents a blockbuster dropped by Takeda in the diabetes market.
Trelagliptin is a once-weekly dipeptidyl peptidase IV (DPP-4) inhibitor that controls blood sugar levels by selectively and continuously inhibiting DPP-4. DPP-4 is an enzyme that can initiate the inactivation of incretin (glucagon-like peptide -1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)), which play an important role in blood glucose regulation. Inhibition of DPP-4 can increase blood sugar level-dependent insulin secretion, thus controlling blood sugar level. Trelagliptin NDA submission is based on efficacy and safety data from several phase III clinical trials conducted in Japanese patients with type 2 diabetes. The efficacy of Trelagliptin has been confirmed in all trials, and it has good safety and tolerability. Trelagliptin Administration once a week can effectively control blood sugar level and is expected to improve patients' medication compliance.    

  • Write your message here and send it to us